Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
10 hedge funds and large institutions have $1.69M invested in Northwest Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
23% less funds holding
Funds holding: 13 → 10 (-3)
48% less capital inflows, than outflows
Capital inflows: $184K | Capital outflows: $352K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sentinus LLC
Oak Brook,
Illinois
|
+$158K |
| 2 |
Moloney Securities Asset Management
Manchester,
Missouri
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ancora Advisors
Cleveland,
Ohio
|
-$329K |
| 2 |
Ethos Financial Group
King Of Prussia,
Pennsylvania
|
-$13.9K |
| 3 |
GW
Grace & White
Ny,
New York
|
-$9.19K |
NWBO Hedge Fund Activity: Q2 2023 in Review
10 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q2 2023, worth a combined $1.69M — down 16% from $2.01M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NWBO and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Sentinus LLC, adding an estimated $158K. The largest seller was Ancora Advisors, exiting entirely with an estimated $329K sold.
- 10 institutional investors held Northwest Biotherapeutics (NWBO) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $1.69M of Northwest Biotherapeutics stock for Q2 2023, down 16% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics positions in Q2 2023 and 3 closed out, a net change of -3 holders.
- The largest Northwest Biotherapeutics buyer in Q2 2023 was Sentinus LLC, an estimated $158K added.
- The largest Northwest Biotherapeutics seller in Q2 2023 was Ancora Advisors, an estimated $329K sold.
Based on aggregated 13F filings for Q2 2023.